Clinical trials
Cholecystitis, Acute trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2013 | 3 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Recruiting | 2 |
| Not yet recruiting | 1 |
| Terminated | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| The University of Texas Health Science Center at San Antonio | 2 |
| Activ Surgical | 1 |
| Baylor College of Medicine | 1 |
| Boston Scientific Corporation | 1 |
| European Society for Trauma and Emergency Surgery | 1 |
| Methodist Health System | 1 |
| Ohio State University | 1 |
| Orlando Health, Inc. | 1 |
| Teleflex | 1 |
| Texas Tech University Health Sciences Center, El Paso | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cholecystitis, Acute | 15 |
| Cholecystitis | 5 |
| Appendicitis | 2 |
| Gallbladder Diseases | 2 |
| Gallstones | 2 |
| Aortic Aneurysm, Abdominal | 1 |
| Bile Duct Diseases | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
| COVID-19 | 1 |
| Cellulitis | 1 |
Trials
Showing 26 to 15 of 15. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.